Gluco6 Ingredients Review 2026: 10 Actives & 525 mg Blend

Label Disclosure and Proprietary Blend Math

The 525 mg figure belongs to the entire seven-ingredient blend, not each ingredient. Dividing it equally would invent seven doses. The three nutrients are listed separately. A defensible comparison uses the blend as an upper bound while recognizing that every component must share that same limited mass.

The published nutrient amounts should not be subtracted from 525 mg: the label lists them outside the proprietary blend. Conversely, 525 mg should not be described as the capsule’s complete fill weight, because separately listed actives and excipients also occupy space. This distinction avoids a misleading mass balance. [label]

This arithmetic does not identify a minimum effective dose, predict the capsule’s effect or justify taking extra capsules. The study context involved a sucrose drink, whereas a mixed-meal study did not reproduce the same beneficial responses. Dose, food matrix and timing all affect whether a comparison transfers. Halschou-Jensen et al. (2015) — PMID 25400106 [mixedmeal]

Ingredient Forms Matter as Much as the Numbers

Chromium is the clearest disclosed comparison: the sample label states 1 mg, equivalent to 1,000 mcg. A cited human trial tested chromium picolinate, while this panel specifies chromium niacinate. Matching the number alone does not establish equivalent absorption, clinical effects or suitability alongside diabetes medication.

For Sukre, the sample artwork supplies a chemical identity—L-arabinose—rather than merely a marketing name. That improves interpretability, but the individual quantity remains hidden. For Gymnema, identifying a leaf does not establish equivalence to a particular standardized extract used elsewhere in research. [label]

For green tea, 65% EGCG is a concentration statement. EGCG mass would equal the unknown extract mass multiplied by 0.65, assuming the label’s percentage basis. It is incorrect to multiply 65% by the entire 525 mg blend and present that result as the actual daily EGCG exposure. [green]

• D3: 50 mcg ×40 IU/mcg =2,000 IU; consider total intake from other products. [vitd]
• B1: 100 mg is a separately disclosed nutrient amount, not a clinical result. [b1]
• TeaCrine: the 200/300 mg research comparator concerns safety; it does not establish glucose control. Taylor et al. (2016) — PMID 26766930 [teacrine]
• Cassia cinnamon: retain the species name; do not silently substitute Ceylon. The historical trial record flags an Expression of Concern. Khan et al. (2003) — PMID 14633804 [cinnamontrial] See the 2025 Expression of Concern (PMID: 40834253) [correction].

Capsule Shell, Excipients and Allergen Screening

The sample label lists hypromellose, microcrystalline cellulose, silicon dioxide, magnesium stearate and stearic acid as other ingredients. These identify formulation materials rather than additional glucose-support doses. The published list does not independently establish allergen cross-contact controls, manufacturing purity or the composition of every delivered batch sold under this name.

Hypromellose is identified as the vegetable capsule shell. Magnesium stearate should not be counted as a separately quantified magnesium supplement. The five excipients have no masses listed, and the manufacturer’s front-page suitability statements are different from a lot-specific allergen declaration or laboratory certificate. [label]

• Match the batch number, expiration date and all active names on the physical bottle.
• Ask the seller about any personally relevant allergy and cross-contact process.
• Request a batch certificate identifying the laboratory, test date and tested analytes.
• Distinguish a recognizable certification from an unexplained manufacturing badge.

A legible label confirms what is represented, while an independent analytical report can address identity, potency or contaminants. Neither document alone proves a therapeutic outcome. Our ingredient hub explains why transparency, quality assurance and clinical efficacy should be assessed separately.

Questions to Bring to a Doctor or Pharmacist

Bring the actual Gluco6 bottle or a clear photograph of its full panel to a clinician. Highlight 1,000 mcg chromium, the seven undisclosed blend doses and other supplements already used. Ask whether the listed forms, total nutrient exposure and medical history make this specific combination appropriate for you.

• Does chromium niacinate fit my medication and monitoring plan? [chromium]
• Do my other products add vitamin D or chromium that changes total exposure?
• Does the label disclose enough green-tea information for my liver history?
• Would a targeted nutrient assessment answer my question better than a multi-ingredient blend?
• What measurements and follow-up would you recommend if you consider this formula appropriate?

For organ-specific warnings and interacting medicines, continue to the Gluco6 safety review. For trial design and endpoint interpretation, use the clinical evidence review and Dietary Supplements Guide. Commercial details stay in the main review’s purchase section rather than being repeated as an ingredient recommendation.

Gluco6 Ingredient FAQs

These five ingredient questions focus on the 525 mg blend, dose estimation, chromium form and the SAMPLE watermark. They explain what can be read directly from the published panel and what remains unknown. None supplies undisclosed ingredient amounts, confirms a delivered batch or establishes clinical benefit for the marketed formula.